medicina51巻4号

2014年04月発行

特集 虚血性心疾患up to date―内科医によるトータルマネジメント 血行再建―PCI，冠動脈バイパス

冠動脈病変の重症度・リスク評価とそれに基づく治療選択

著者： 田中悌史¹

所属機関： ¹東京大学医学部附属病院循環器内科

ページ範囲：P.698 - P.702

ポイント

◎冠動脈疾患の治療方針は冠動脈病変の重症度のみならず，患者状態・心機能・合併疾患などさまざまな観点からリスク評価を行い決定される．

◎患者の症状を改善しQOLを向上する目的，生命予後を改善する目的の両面から治療の妥当性を判断する必要がある．

◎適切な重症度・リスク評価を行い各施設の体制・技量・成績を考慮したうえで，循環器内科・心臓外科が慎重な検討を行い，治療方針を決定する．

参考文献

1）Ryan TJ, et al：Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assesment of Diagnostic and Therapeutic Cardiovascular Procedures（Subcommittee on Percutaneous Transluminal Coronary Angioplasty）. Circutation 78：486-502, 1988

2）Sianos G, et al：The SYNTAX score；An angiographic tool grading the complexity of coronary artery disease. EuroIntervention 1：219-227, 2005

3）Nachef SAM, et al：EuroSCORE II. Eur J Cardiothorac Surg 41：734-745, 2012

4）Banning AP, et al：Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease. J Am Coll Cardiol 55：1067-1075, 2010

5）Boden WE, et al：Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356：1506-1516, 2007

6）Nishigaki K, et al；Percutaneous coronary intervention plus medical therapy reduces the incidence of acute coronary syndrome more effectively than initial medical therapy only among patients with low-risk coronary artery disease a randomized, comparative, multicenter study. JACC Cadiovasc Interv 1：469-479, 2008

7）Hueb W, et al：Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study（MASS II）；A randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 122：949-957, 2010

8）Serruys PW, et al：Percutaneous coronary intervention veusus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 360：961-972, 2009

9）Kappetein AP, et al：Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease；3-year follow-up of the SYNTAX trial. Eur Heart J 32：2125-2134, 2011

10）Mohr FW, et al：Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease；5-year follow-up of the randomized, clinical SYNTAX trial. Lancet 381：629-638, 2013